NCT03381833 - A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2017

Primary Completion Date

December 3, 2019

Study Completion Date

January 14, 2020

Conditions

Beta-Thalassemia

Interventions

DRUG

LJPC-401

subcutaneous injection, up to 20 mg per week from week 26 to 52

DRUG

LJPC-401

subcutaneous injection, up to 20 mg per week from week 1 to 52

Trial Locations (22)

2050

Investigative Site, Camperdown

2170

Investigative Site, Liverpool

10021

Investigative Site, New York

10043

Investigative Site, Orbassano

10700

Investigative Site, Bangkok Noi

26504

Investigative Site, Patra

35100

Investigative Site, Izmir

37134

Investigative Site, Verona

41124

Investigative Site, Modena

50200

Investigative Site, Chiang Mai

54642

Investigative Site, Thessaloniki

80138

Investigative Site, Napoli

94609

Investigative Site, Oakland

115 27

Investigative Site, Goudi

09121

Investigative Site, Cagliari

1107 2020

Investigative Site, Beirut

01330

Investigative Site, Adana

06100

Investigative Site, Ankara

07059

Investigative Site, Antalya

07160

Investigative Site, Antalya

E1 1BB

Investigative Site, London

N19 5NF

Investigative Site, London